



## Organizational and Personnel Changes

TOKYO, April 25, 2022 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced the following organizational and personnel changes, effective July 1, 2022.


### [Details of Organizational Changes]

#### 1. Reorganization of Pharmaceutical Technology Div.

Pharmaceutical Technology Div. currently has two functions: the R&D function for pharmaceutical technology (PT) including technical research, and the manufacturing function to supply high-quality investigational drugs and products in a stable and efficient manner, in cooperation with a manufacturing subsidiary Chugai Pharma Manufacturing Co., Ltd. (CPMC). Two separate divisions will be in place to further enhance these functions which play a key role in realizing TOP I 2030.

- Pharmaceutical Technology Div. will be divided into Pharmaceutical Technology Div., which is centered on the PT R&D function, and Manufacturing Technology Div., which is centered on the manufacturing function. Related departments will be also reorganized.
- Pharmaceutical Technology Div. will include PT Planning & Coordination Dept., CMC Regulatory Affairs Dept., API Process Development Dept., Formulation Development Dept., and Analytical Development Dept. Manufacturing Technology Div. will consist of Supply Chain Management Dept., Quality Management Dept. and CPMC.

[Structure after reorganization]



#### 2. Reorganization of Marketing & Sales Div.

In order to further strengthen the expertise and to concentrate on growth and new areas, the region-based sales organization will be changed into a disease area-based system focusing on the two diseases areas of oncology and specialty diseases, considering the changes in the healthcare industry and the Company's portfolio of products and projects under development. The 36 sales branches in Japan will also be reorganized into 33 branches. Back office operations in regional management offices will be consolidated and centralized to enable efficient and fast collaboration with related organizations.

- Hokkaido & Tohoku Regional Management Office will be renamed Kita-Nihon Regional Management Office
- Oncology Marketing & Sales Promotion Dept. and Primary Marketing & Sales Promotion Dept. will be renamed Oncology Marketing Dept. and Specialty Marketing Dept., respectively.

### 3. Other renames

Considering the portfolio of products and projects under development, "Primary" used in the names of organizations will be replaced with "Specialty."

New Name	Current Name
Specialty Lifecycle Management Dept. Project & Lifecycle Management Unit	Primary Lifecycle Management Dept. Project & Lifecycle Management Unit
Specialty Clinical Development Dept. Clinical Development Div.	Primary Clinical Development Dept. Clinical Development Div.

#### [Details of Personnel Changes]

##### Vice President

Name	New Responsibilities	Current Responsibilities
Shinya Takuma	Vice President Head of Manufacturing Technology Div. and President of Chugai Pharma Manufacturing Co., Ltd.	Vice President Head of Pharmaceutical Technology Div. and President of Chugai Pharma Manufacturing Co., Ltd.

##### Associate Vice President

Name	New Responsibilities	Current Responsibilities
Takanori Muto	Associate Vice President Head of Pharmaceutical Technology Div.	Associate Vice President Deputy Head of Pharmaceutical Technology Div. and Head of PT Planning Dept., Pharmaceutical Technology Div.

##### Department Heads

Name	New Responsibilities	Current Responsibilities
Motegi Hiroshi	Head of Specialty Lifecycle Management Dept., Project & Lifecycle Management Unit	Head of Primary Lifecycle Management Dept., Project & Lifecycle Management Unit
Hosoi Yosuke	Head of Quality Initiative Dept., Quality & Regulatory Compliance Unit	Head of Business Strategy & Compliance Dept., Quality & Regulatory Compliance Unit
Hasegawa Koichi	Head of Business Strategy & Compliance Dept., Quality & Regulatory Compliance Unit	Head of Strategy Development Group, Business Strategy & Compliance Dept., Quality & Regulatory Compliance Unit

Department Heads (cont.)

Name	New Responsibilities	Current Responsibilities
Shindoh Fuminori	Head of Specialty Clinical Development Dept., Clinical Development Div.	Head of Primary Clinical Development Dept., Clinical Development Div.
Ueda Yasufumi	Head of PT Planning & Coordination Dept., Pharmaceutical Technology Div.	Head of CMC Development Dept. and Deputy Head of CMC Development Dept., Pharmaceutical Technology Div.
Ebihara Shinichi	Head of CMC Regulatory Affairs Dept., Pharmaceutical Technology Div.	Deputy Head of API Process Development Dept., Pharmaceutical Technology Div.
Shimizu Motoki	Head of Quality Management Dept., Manufacturing Technology Div.	Head of PT Quality Dept., Pharmaceutical Technology Div.
Murata Maki	Head of North Japan Regional Management Office, Marketing & Sales Div.	Head of Hokkaido & Tohoku Regional Management Office, Marketing & Sales Div.
Takano Junichi	Head of Oncology Marketing Dept., Marketing & Sales Div.	Head of Oncology Marketing & Sales Promotion Dept., Marketing & Sales Div.
Saito Koji	Head of Specialty Marketing Dept., Marketing & Sales Div.	Head of Primary Marketing & Sales Promotion Dept., Marketing & Sales Div.

###